Paroxysmal nocturnal hemoglobinuria (PNH) is a rare acquired disorder first described in the latter half of the 19th century.
1 Though traditionally classified among the hemolytic anemias, the disease affects all circulating hematopoietic elements with many patients presenting with thromboses or cytopenias.
2 PNH is a primitive stem cell disorder with the clonality described in the 1970s by enzyme marker studies and is best classified among the myelodysplastic syndromes. 3 Molecular investigations have revealed a deficiency in the major membrane anchoring protein, glycosyl-phosphatidylinositol (GPI) phospholipid, with concomitant reduction in these GPI-linked cell-surface proteins including the complement-neutralizing proteins, 4 the lack of which results in mature blood elements and progenitors being susceptible to the action of complement. GPI synthesis involves at least 10 genes, yet all patients with PNH have heterogeneous abnormalities in only one, the Xlinked PIG-A gene. 5 Inability to anchor other GPI linked proteins probably Correspondence: Dr MA Doukas, VAMC (111-E), 2250 Leestown Rd, Lexington, KY 40511-1093, USA Received 6 November 1997; accepted 3 February 1998 explains certain complications in this disorder, seemingly unrelated to its hemolytic component. Most significant is the propensity for venous thromboses that may involve almost any organ or site and is the leading cause of death in this disease. 6 The most common sites of these thromboses are the portal, hepatic and splenic circulations. 7 Infections occur at a disproportionately high rate among these patients, and were responsible for death in 11 of 51 patients in one series, 8 possibly occurring secondary to leukocyte dysfunction. Finally, patients with PNH may develop aplastic anemia or, as with other myelodysplastic syndromes, acute myeloblastic leukemia.
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These considerations have led to the use of bone marrow transplantation, both syngeneic and allogeneic, in PNH associated with aplasia. 10 As patients with PNH in 'chronic phase' may live for years, with a median survival estimated at 10 years in one study, 9 there has been a reluctance to proceed with transplantation unless aplasia has also developed. As management in marrow transplantation has improved however, other 'chronic' hematologic diseases with significant morbidity and mortality, such as the thalassemias, are now being considered.
We describe a patient with PNH without aplasia successfully transplanted with syngeneic marrow. This patient, according to flow cytometry parameters, has been cured of her disorder.
Case report
A 21-year-old white female was first noted to have a hematologic abnormality in March 1980 during the seventh month of her third pregnancy when a hematocrit of 23% was documented. Evaluation revealed increased reticulocytes, LDH and bilirubin. There were no spherocytes and the Coombs' test was negative. She had normal folate and B 12 levels and bone marrow aspirate revealed erythroid hyperplasia. A further evaluation in June 1980 revealed a normal hemoglobin electrophoresis, negative Ham's test, normal osmotic fragility and no red cell enzyme deficiencies. She was given an empiric trial of folate and iron.
She was re-evaluated when first referred to this institution in July 1982. During the interim she had noted 'blood' in the urine for the first time and also related exposures to plastics (knife factory) and pesticides (from her husband's work exposures on his clothing). Physical examination revealed pallor, mild scleral icterus, and a spleen tip 2 cm below the left costal margin with deep inspiration. Hematocrit was 17.7%; white count was 7000, and platelet 132 000 with 14% reticulocytes. She had an elevated serum-free hemoglobin of 71, and negative direct and indirect Coombs' test, normal osmotic fragility and a positive Ham's and sugar water test. Bone marrow revealed no stainable iron, erythroid hyperplasia, and a normal chromosome pattern. She commenced 60 mg prednisone a day with subsequent normalization of platelet counts and stabilization of hematocrit (25-30%), albeit with a persistent reticulocytosis.
In October 1982, repeat Ham's and sugar water tests remained positive. A blood sample was sent to Duke University and reported as having 25% type III PNH cells. Shortly thereafter in November the patient developed left deep venous thrombophlebitis with visualization of multiple clots below the level of the popliteal fossa. She was at this time receiving birth control pills and smoking two packs of cigarettes per day. She was treated with high-dose heparin and then switched to coumadin, without complications.
On 4 January 1983 she was evaluated for bone marrow transplantation from her identical twin sister. At this admission she was noted to be Cushingoid with an acneiform eruption and left calf 1 cm larger in circumference than the right. The hematocrit was 29.7%, white count 10 600, platelets 283 000, total bilirubin 1.3, SGOT 94, SGPT 124, and LDH 1340. A liver biopsy revealed hemosiderosis only. ABO blood typing and dermatologlyphic analysis confirmed identical twinness.
After informed consent with an approved institutional transplantation protocol, the patient was begun on a conditioning regimen consisting of a total dose of 96 mg busulfan over 4 days by mouth, followed by a total dose of 2400 mg of cytoxan over 4 days intravenously. On the day after the last cytoxan dose, the patient's identical twin underwent marrow harvest. Immediately prior to the institution of the conditioning regimen, isolation of the patient in a laminar air flow room and the initiation of bactrim prophylaxis was instituted. After an uncomplicated course the patient achieved complete hematopoietic recovery.
Flow cytometry methods
Five hundred microliters of whole blood anticoagulated with ACD is washed three times in PBS and resuspended to a concentration of 1 × 10 7 cells/ml. Then 100 l of this preparation is mixed with 5 l of anti-CD59PE conjugate (Caltag, San Francisco, CA, USA) and 10 l of an isotope control with PE conjugate (Becton Dickinson, San Jose, CA, USA) for 15 min at room temperature. Cells are then washed and resuspended in PBS. Cells are analyzed on a FACScan flow cytometer (Becton Dickinson) first with settings for RBCs and then with standard WBC settings. The sample is gated to isolate RBCs, lymphocytes, monocytes and granulocytes. Single color histograms for CD59 and the isotype control are printed for each cell type. In addition to the patient sample, a known positive PNH sample and a negative control are run.
Results

Clinical
The patient recovered post-transplant without event and on repeated testing, showed no evidence of PNH red cells by complement lysis sensitivity. Over the ensuing years, the patient had no recurrence of thrombosis, abdominal pain or dark urine. In March 1987, she gave birth to female fraternal twins, now 10 years old, who are developing normally. Her most recent CBC was normal with Hct 44%. She continues to have normal menses and normal thyroid function.
Flow cytometry
The patient's sample shows only a single population of red cells, lymphocytes, monocytes and granulocytes on the CD59 plot. The fluorescent intensity is the same as the negative control showing a normal level of expression of the CD59 epitope on both red cells (Figure 1 ) and lymphocytes, monocytes and granulocytes (Figure 2 ). There is no evidence of a subpopulation with weak CD59 expression as in the PNH positive control (data not shown).
Discussion
Paroxysmal nocturnal hemoglobinuria is a chronic, acquired dysplastic disorder with protean manifestations. The patient described here, with a history of thrombosis and sequelae of chronic steroid administration, underwent syngeneic marrow transplantation as the only potentially curative therapy for her disease. Thrombosis is highly associated (39% of patients) with this disorder and is often related to the patient's demise. 2 It should be noted that while considered 'chronic', estimates of median survival after diagnosis are 10 years.
2 This patient was diagnosed relatively early while in her 20s. Prior exposure to toxic chemicals is of interest, although no epidemiological or molecular connection to the acquired genetic defect of the PIG-A gene is known.
The linkage of genetic aberrations of the PIG-A (GPI) anchored complement inhibitors has allowed a clearer understanding of this descriptive diagnosis. 5 Over a dozen proteins are either greatly diminished or undetectable on the abnormal PNH cells. 4 This gene has been localized to the X chromosome (Xp22.1) where a single mutagenic locus gives rise to the PNH phenotype due to single carriage in males and Lyonization (inactivation of one X) in females. Study of X-linked polymorphisms has confirmed the hematopoietic clonality, with support for a totipotent origin due to discovery of the phenotype on all blood elements. 4 The stem cell nature of the genetic lesion is reinforced further by demonstration of the same lesion in T and B cell lines derived from affected patients. However, the description of two different PIG-A mutations in a natural killer-derived cell line 11 and the description of two inde- pendent PNH clones in two individuals 12 adds complexity to the disease process. What is striking is the marked heterogeneity of mutations within the PIG-A coding sequence, 5, 12 with a predominance of frameshift forms reported by some, 13 and geographic/ethnic variances in these mutations noted by others.
14 Whether this apparent heterogeneity can be linked to the heterogeneity in clinical presentations and outcomes remains to be established.
A better understanding of thrombotic events may evolve with the recognition of the molecular basis of this complex disorder. Several theories, with varying degrees of scientific support have been advanced to explain the hypercoagulability in PNH. The first connects the loss of CD59 on platelets with an increase in formation of polymeric C9 complexes/vesicles in response to the activation of a given amount of complement, with a resultant increased generation of thrombin. 15 Another proposes the absence of the receptor of the urokinase-type plasminogen activator (u-PAR) on blood monocytes and granulocytes. 16 The lack of this receptor may lead to greater clot stability thereby promoting the vascular events described in PNH patients. Reagents are now available that enable GPI-anchored surface proteins to be detected at a high level of sensitivity for monitoring treated PNH patients 17 and may well supplant the classic Ham's test for diagnosis. Immunophenotyping for PNH after transplant was first reported in 1992, 18 albeit with only a 10-month follow-up, and utilized leukocyte-associated antigens (CD14, CD16). Our patient has attained very long follow-up such that all cell types examined, including long-lived lymphocyte populations, were normal in CD59 density. While transplantation for this disorder is well described with twin and histocompatible or haploidentical donors, 10, 19 the majority of cases were transplanted for aplastic anemia or a severe cytopenia. Less common reasons for transplantation include recurrent hemolytic episodes, red cell alloantibodies, difficulty with transfusion support, abdominal pain and one case described as life-threatening deep vein thrombosis, neurologic symptoms and persistent anemia (Ref. 10, patient 8) . It is of interest that the patient chose to bear children after intensive therapy, was able to do so, and that the children are developing normally. The experience with syngeneic stem cell transplantation in PNH has demonstrated the importance of marrow ablative therapy in view of the persistence of the abnormal clone in some cases. 19 PNH is a chronic, acquired stem cell disorder related to a mutation of the PIG-A gene, resulting in an array of clinical problems. Transplantation in selected cases is curative and monitoring of these patients is greatly enhanced with the use of modern immunophenotyping. It remains to be seen if this sensitive, noninvasive monitoring capability will be capitalized upon by a resurgence in the study of non-transplant therapies for this disorder.
